A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV)...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2020-11-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/10254.pdf |
| _version_ | 1797420202133028864 |
|---|---|
| author | Dongping Rao Meiqin Fu Yingjie Chen Qing Liu Lin Xiao Xin Zhang Zhongxiao Li Haitao Li Yongyi He Yongxing Chen Jieying Chen Jin Hu Yanming Huang |
| author_facet | Dongping Rao Meiqin Fu Yingjie Chen Qing Liu Lin Xiao Xin Zhang Zhongxiao Li Haitao Li Yongyi He Yongxing Chen Jieying Chen Jin Hu Yanming Huang |
| author_sort | Dongping Rao |
| collection | DOAJ |
| description | For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening. |
| first_indexed | 2024-03-09T06:59:14Z |
| format | Article |
| id | doaj.art-83b689861b984078a51f6957f40e15fd |
| institution | Directory Open Access Journal |
| issn | 2167-8359 |
| language | English |
| last_indexed | 2024-03-09T06:59:14Z |
| publishDate | 2020-11-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj.art-83b689861b984078a51f6957f40e15fd2023-12-03T09:56:52ZengPeerJ Inc.PeerJ2167-83592020-11-018e1025410.7717/peerj.10254A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control studyDongping Rao0Meiqin Fu1Yingjie Chen2Qing Liu3Lin Xiao4Xin Zhang5Zhongxiao Li6Haitao Li7Yongyi He8Yongxing Chen9Jieying Chen10Jin Hu11Yanming Huang12Department of Medical Records, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaDepartment of Preventive Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaDepartment of Radiotherapy, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaDepartment of Medical Records, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaDepartment of Ear-Nose-Throat, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaClinical Laboratory, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaDepartment of Respiratory Medicine, Clinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, ChinaFor populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening.https://peerj.com/articles/10254.pdfNasopharyngeal carcinomaScreeningMarkerEpstein-Barr viruscombination |
| spellingShingle | Dongping Rao Meiqin Fu Yingjie Chen Qing Liu Lin Xiao Xin Zhang Zhongxiao Li Haitao Li Yongyi He Yongxing Chen Jieying Chen Jin Hu Yanming Huang A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study PeerJ Nasopharyngeal carcinoma Screening Marker Epstein-Barr virus combination |
| title | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
| title_full | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
| title_fullStr | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
| title_full_unstemmed | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
| title_short | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
| title_sort | combination of two elisa tests for nasopharyngeal carcinoma screening in endemic areas based on a case control study |
| topic | Nasopharyngeal carcinoma Screening Marker Epstein-Barr virus combination |
| url | https://peerj.com/articles/10254.pdf |
| work_keys_str_mv | AT dongpingrao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT meiqinfu acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yingjiechen acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT qingliu acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT linxiao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT xinzhang acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT zhongxiaoli acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT haitaoli acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yongyihe acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yongxingchen acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT jieyingchen acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT jinhu acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yanminghuang acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT dongpingrao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT meiqinfu combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yingjiechen combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT qingliu combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT linxiao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT xinzhang combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT zhongxiaoli combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT haitaoli combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yongyihe combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yongxingchen combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT jieyingchen combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT jinhu combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT yanminghuang combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy |